ImmunityBio
IBRX
49 hedge funds and large institutions have $17.5M invested in ImmunityBio in 2020 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 12 closing their positions.
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
4% more funds holding
Funds holding: 47 → 49 (+2)
0.35% more ownership
Funds ownership: 5.84% → 6.19% (+0.35%)
10% less call options, than puts
Call options by funds: $316K | Put options by funds: $351K
19% less capital invested
Capital invested by funds: $21.8M → $17.5M (-$4.22M)
28% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.59M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.14M |
| 3 |
Goldman Sachs
New York
|
+$403K |
| 4 |
Morgan Stanley
New York
|
+$278K |
| 5 |
Renaissance Technologies
New York
|
+$276K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$633K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$475K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$463K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$277K |
| 5 |
OGC
One68 Global Capital
New York
|
-$230K |
IBRX Hedge Fund Activity: Q1 2020 in Review
49 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q1 2020, worth a combined $17.5M — down 19% from $21.8M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new IBRX positions and 12 closed out — a net gain of 3 holders — while 13 added to existing stakes and 18 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.59M. The largest seller was JP Morgan Chase, cutting an estimated $633K.
- 49 institutional investors held ImmunityBio (IBRX) as of Q1 2020, up from 47 in Q4 2019.
- Funds reported $17.5M of ImmunityBio stock for Q1 2020, down 19% quarter-over-quarter.
- 15 funds opened new ImmunityBio positions in Q1 2020 and 12 closed out, a net change of +3 holders.
- The largest ImmunityBio buyer in Q1 2020 was Vanguard Group, an estimated $1.59M added.
- The largest ImmunityBio seller in Q1 2020 was JP Morgan Chase, an estimated $633K sold.
Based on aggregated 13F filings for Q1 2020.